Molplex Pharmaceuticals develops portfolios of new medicines, translating early research into clinical products. We develop both proprietary and partnered projects with a focus in rare, niche and specialty conditions. Our proprietary portfolio contains 6 new therapies across oncology and infection, affecting a total of over 9 million people per year worldwide.

Molplex bridges the gap between early research and clinic-ready products with our proprietary technology Optiplex, an Artificial Intelligence system continuously extracting knowledge from scientific Big Data. Optiplex predicts the efficacy and side effects of potential drugs, therefore estimating the outcome of drug trials before these are conducted in man for the first time. Optiplex drives our robotic laboratory systems to produce the best possible drug candidates optimised for efficacy, dosing and minimal side effects. Our systems achieve this using minimal amount of time and capital.